For the purpose of designing the patient-based model for Dementia with Lewy Bodies (DLB), the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of ...

Audio pioneer Dolby Laboratories (DLB) has made significant strides recently. The company has partnered with brands such as ...

Dolby Laboratories (DLB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Dolby Laboratories (DLB) reported $357 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 13.1%. EPS of $1.14 for the same period compares to $1.01 a ...

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...

We are neutral on Dolby Labs due to limited upside potential despite revenue growth and strong balance sheet in FQ1 2025. Read an analysis of DLB stock here.

Dolby Laboratories (NYSE:DLB – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Friday. A number of other ...

The Lady Lakers hosted the South Prairie-Max Royals at the dock for some region 3 basketball action. The Royals held a 17 ...

Dolby Laboratories (DLB) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.01 per share a year ago.

About Dementia with Lewy Bodies (DLB) DLB is the third most common degenerative disease of the brain (after Alzheimer’s disease and Parkinson’s disease), with approximately 700,000 individuals ...